Un-audited Financial Results for the Quarter Ended 30th June, 2026

Date: 12th August, 2026 The Manager Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort Mumbai-400001 Scrip Code: 524516 Scrip Id: BACPHAR Sub: Outcome of Board Meeting Held on August 12th, 2026 Dear Sir, Pursuant to provisions of Regulation 30 and Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held today i.e. August 12, 2026 have discussed and approved the following key matters: 1. Unaudited Financial Results for the quarter ended 30th June, 2026; The Board has approved the Unaudited Financial Results of the Company for the quarter ended 30th June, 2026. The financial results will be submitted to the exchange and made available on the Company’s website. 2. Review of other business activities The meeting of the Board of Directors commenced at 03.00P.M. and concluded at 04:00P.M. The results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 in due course. Submission for information and necessary update. Kindly take the above on your record. Thanking you, Yours faithfully, For Bacil Pharma Limited Ms. Chaitali Kalpataru Shah Director & CFO DIN: 11167778 BACIL PHARMA LIMITED {CIN : L24200MH1987PLC043427} Unaudited Financial Results for the Quarter Ended 30th June,2026 Prepared In Compliance with the Indian Accounting Standards (IND AS) (₹ in Lakhs) Quarter ended Year ended Particulars 30-06-2026 31-03-2026 30-06-2025 31-03-2026 (Unaudited) Audited (Unaudited) Audited 1 Revenue from operations - - Other income 8.91 11.34 100.30 123.52 Total revenue 8.91 11.34 100.30 123.52 2 Expenses Cost of material consumed - - - - Purchases of Stock in trade - - - - Employee benefits expense 0.72 0.00 3.00 4.89 Finance Cost - - - - Depreciation and amortization expense - - - - Other expenses 1.55 7.45 7.90 19.61 Total expenses 2.27 7 .45 10.90 24.50 Profit / (Loss) from ordinary activities before tax 6.64 3.89 89.40 99.02 3 Tax expense: Current tax 0 - 22.50 - Deferred tax 8.25 58.27 - 56.53 4 Profit/(Loss) from ordinary activities after tax (1.61) 62.16 66.90 155.55 5 Other Comprehensive Income (OCI) Item that will not be reclassified to profit or loss Gain/(Loss) on recognised on fair valuation of Financial Assets 31.73 -226.30 - (217.43) Income tax relating to these items 0 0 - - Total Other Comprehensive Income (OCI) 31.73 ( 226.30) - (217.43) Profit/(Loss) for the Period 30.12 ( 164.14) 66.90 (61.88) Paid up Equity Share Capital (Face Value of Rs. 10 each) 1 ,397.03 1,397.03 1,397.03 1,397.03 6 Earning Per Share ( EPS ) (Not annualised) (1) Basic 0.22 0 .44 0.48 1.11 (2) Diluted 0.22 0 .44 0.48 1.11 See notes accompanying to the Financial statements Notes: TheaforesaidunauditedfinancialresultshavebeenreviewedandrecommendedbyAuditCommitteeandapprovedbytheBoardofDirectorsattheir meeting held on 12-08-2026 TheStatutoryAuditorsoftheCompanyhavecarriedouta'LimitedReview"oftheaboveresultsasperregulations33ofSEBI(ListingObligationsand Disclosures Requirements) Regulations, 2015. ThefiguresfortheQuarter/Yearended30thJune,2026areincompliancewiththeIndianAccountingStandards(IndAS)notifiedbytheMinistryof Corporate Affairs. TheFinancialresultshavebeenpreparedinaccordancewiththerecognitionandmeasurementprincipleslaiddowninIndianAccountingStandard34– 4 InterimFinancialreporting,notifiedundersection133oftheCompaniesAct,2013readwithCompanies(IndianAccountingStandards)Rules,2015,as amended from time to time, and other accounting principles generally accepted in India. TheformatforaboveresultsasprescribedinSEBI'scircularCIR/CFD/CMD/15/2015datedNov30,2015hasbeenmodifiedtocomplywiththe 5 requirementsofSEBI'scirculardatedJuly5,2016,IndASandScheduleIII[DivisionII]totheCompaniesAct,2013applicabletocompaniesthatare required to comply with Ind As. 6 The Company has only one reportable primary pharmaceutical business segment as per IND AS 108 . Figuresforthepreviousperiodhavebeenregrouped,reclassifiedandrestatedwherevernecessarytomakethemcomparablewiththecurrentperiod's figures. For and on behalf of the Board Bacil Pharma Limited Ms Chaitali Kalpataru Shah Director & CFO DIN : 11167778 SARANG SHIVAJIRAO CHAVAN CA S +9A 1R 9A 9N 7G C 6H2A3V1A5N4 *\ AND ASSOCIATES INDIA CHARTERED ACCOUNTANTS avansarangl@gmailo .com LIMITED REVIEW REPORT ON UNAUDITED STANDALONE QUARTERLY FINANCIALS RESULTS OF BACIL PHARMA LIMITED PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS,2015. To the Board of Directors of BACIL PHARMA LIMITED We have accompanying statement of unaudited financial results of BACIL PHARMA LIMITED (the “Company”) for the Quarter ended 30" June, 2026 (the “Statement”) on Standalone basis attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “listing Regulations”). 1) We have reviewed the accompanying statement of unaudited financial results of BACIL PHARMA LIMITED (the “Company”) for the Quarter ended June 30, 2026 (the “Statement”) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “listing Regulations”). 2) Company’s Board of Directors responsibility of the Company’s Management and Approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act,2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in india . 35, 4th Floor, Shree Krishna Tower, Near Navrangpu Navrangpura- 380009 SARANG SHIVAJIRAO CHAVAN CA SARANG CHAVAN +919974 623154 *\ AND ASSOCIATES INDIA chavansarangl@gmail.com CHARTERED ACCOUNTANTS 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of the Interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. 4) The information and data contained in this report are based solely on the documents, explanations, and representations provided by the management of the entity. We have not independently verified the correctness or completeness of such information and records, and our verification has been limited to the extent of information made available to us during the course of our review. Other Matters We have carried out the limited review of the financial results of the Company for the quarter ended June 30, 2026 . There is no other qualification in these regards on these financial results. SARANG SHIVAJIRAO CHAVAN AND ASSOCIATES CHARTERED ACCOUNTANTS FRN: J59649W CASARANG CHAVAN (PROPRIETOR) M.NO.142576 UDIN: 26142576TSPRYS4898 Date: 12/08/2026 Place: Ahmedabad 35, ath Floor, Shree Krishna Tower, Near Navrangpura Jain Derasar, Navrangpura- 380009